publication . Article . 2016

Efectos farmacogenéticos de inhibidores de la enzima convertidora de la angiotensina en variaciones de urea y creatinina asociadas con el envejecimiento en pacientes con demencia de la enfermedad de Alzheimer

Ferreira de Oliveira, Fabricio; Berretta, Juliana Marília; Suchi Chen, Elizabeth; Cardoso Smith, Marilia; Ferreira Bertolucci, Paulo Henrique;
Open Access English
  • Published: 30 Jun 2016
  • Publisher: Universidad del Valle
Background: Renal function declines according to age and vascular risk factors, whereas few data are available regarding geneticallymediated effects of anti-hypertensives over renal function. Objective: To estimate urea and creatinine variations in dementia due to Alzheimer disease (AD) by way of a pharmacogenetic analysis of the anti-hypertensive effects of angiotensin-converting enzyme inhibitors (ACEis). Methods: Consecutive outpatients older than 60 years-old with AD and no history of kidney transplant or dialytic therapy were recruited for prospective correlations regarding variations in fasting blood levels of urea and creatinine in one year, considering A...
free text keywords: Alzheimer disease, pharmacogenetics, urea, creatinine, Renin-Angiotensin System, Enfermedad de Alzheimer, farmacogenética, creatinina, sistema reninaangiotensina

1. Higuchi M, Chen R, Abbott RD, Bell C, Launer L, Ross GW, et al.

Mid-life proteinuria and late-life cognitive function and dementia in elderly men: eTh Honolulu-Asia aging study.  Alzheimer Dis Assoc Disord. 2015; 29: 200-5.  2. Hadjadj S, Tarnow L, Forsblom C, Kazeem G, Marre M, Groop PH, et al. Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: Case-control, haplotype, and family-based study in three european populations. J Am Soc Nephrol. 2007; 18: 1284-91.  3. Peters R, Beckett N, Poulter R, Burch L, Narkiewicz K, Fagard R, et al. Kidney function in the very elderly with hypertension: data from the hypertension in the very elderly (HYVET) trial. Age Ageing. 2013; 42: 253-8.  4.  Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JCM. ACE Polymorphisms. Circ Res. 2006; 98: 1123-33.  5.  De Oliveira FF, Bertolucci PHF, Chen ES, Smith MC. Brainpenetrating angiotensin-converting enzyme inhibitors and cognitive change in patients with dementia due to Alzheimer's Disease. J Alzheimers Dis. 2014; 42: S321-4.  6.  Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: eTh implications of systematic meta-analyses.  Nature Rev Neurosci. 2008; 9: 768-78.  7. Kehoe PG, Katzov H, Andreasen N, Gatz M, Wilcock GK, Cairns NJ, et al. Common variants of ACE contribute to variable age-atonset of Alzheimer's disease. Hum Genet. 2004;114:478-483.

8. Chung C-M, Wang R-Y, Fann CSJ, Chen JW, Jong YS, Jou YS, et al . Fine-mapping angiotensin-converting enzyme gene: Separate QTLs identified for hypertension and for ACE activity.  PLoS One. 2013; 8: e56119.  9.  Martínez-Rodríguez N, Posadas-Romero C, Villareal-Molina T, Vallejo M, Del-Valle-Mondragón L, Ramírez-Bello J, et al.

Single nucleotide polymorphisms of the angiotensin-converting enzyme (ACE) gene are associated with essential hypertension and increased ACE enzyme levels in Mexican individuals.  PLoS One. 2013; 8: e65700.  10. Brugts JJ, Isaacs A, de Maat MPM, Boersma E, van Duijn CM, Akkerhuis KM, et al. A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensinconverting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. J Hypertens. 2009; 29: 509-19.  11. Zhang N, Cui H, Yang L. Eefct of angiotensin II type I receptor A1166C polymorphism on benazepril action in hypertensive patients: A family-based association test study. Arch Pharm Res.

2012; 35: 1817-22.  12. Schuch JB, Constantin PC, da Silva VK, Korb C, Bamberg DP, da Rocha TJ, et al. ACE polymorphism and use of ACE inhibitors: eefcts on memory performance. Age. 2014; 36: 1515-22.

13.  McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr, Kawas CH, et al. eTh diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement. 2011; 7: 263-9.  14. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, et al. eTh seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure - the JNC 7 report. JAMA. 2003; 289: 2560-72.  15.  Kim TH, Chang HS, Park SM, Nam BY, Park JS, Rhim T, et al. Association of angiotensin I-converting enzyme gene polymorphisms with aspirin intolerance in asthmatics.  Clin Exp Allergy. 2008; 38: 1727-37.  16. Irvin MR, Lynch AI, Kabagambe EK, Tiwari HK, Barzilay JI, Eckfeldt JH, et al. Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study.  J Hypertens. 2010; 28: 2076-83.  17. Stewart R, Xue Q-L, Masaki K, Petrovitch H, Ross GW, White LR, et al. Change in blood pressure and incident dementia: A 32- year prospective study. Hypertension. 2009; 54: 233-40.

18.  De Oliveira FF, Bertolucci PHF, Chen ES, Smith MC. Risk factors for age at onset of dementia due to Alzheimer's disease in a sample of patients with low mean schooling from São Paulo, Brazil.Int J Geriatr Psychiatry. 2014; 29: 1033-9.  19.  De Oliveira FF, Pivi GAK, Chen ES, Smith MC, Bertolucci PHF. Risk factors for cognitive and functional change in one year in patients with Alzheimer's disease dementia from São Paulo, Brazil. J Neurol Sci. 2015; 359: 127-32. 

Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue